



91 E05 #7158 1636
8/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DE SANTIS, Rita

Atty. Ref.: 2818-64

Serial No. 09/981,239

Group: 1636

Filed: October 18, 2001

Examiner: Qian

For: ANTIGEN PRESENTING CELLS, METHOD FOR THEIR
PREPARATION AND THEIR USE FOR CANCER
VACCINES

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

AUG 14 2002

TECH CENTER 1600/2900

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action] *N/C*
- ☐ 2. **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance] *N/C*
- ☒ 3. **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance] *\$180.00*
- ☐ 4. **Pursuant to 37 CFR 1.97(d)**
[before Issue Fee payment] *\$180.00*

The following are submitted in the above-identified application in compliance with 37
C.F.R. §§ 1.97 and 1.98:

- ☒ 5. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of each non-
English language document is enclosed herewith.

This paper is submitted in accordance with:

08/08/2002 NGUYEN 00000067 09981239

01 FC:126

180.00 DP




- ☐ 6. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 7. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 9 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 10 below.
- ☐ 8. 37 CFR §1.97(d): [before issue fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 9 below.
- ☐ 9. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 10. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

DE SANTIS, Rita
Serial No. 09/981,239

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

BJS:plb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100